Irisin attenuates type 1 diabetic cardiomyopathy by anti-ferroptosis via SIRT1-mediated deacetylation of p53

• Published in: Cardiovascular diabetology 2024-04, Vol.23 (1), p.116-116, Article 116
• Main Authors: Tang, Yuan-Juan, Zhang, Zhen, Yan, Tong, Chen, Ken, Xu, Guo-Fan, Xiong, Shi-Qiang, Wu, Dai-Qian, Chen, Jie, Jose, Pedro A, Zeng, Chun-Yu, Fu, Jin-Juan
• Format: Article
• Language: English
• Subjects: Acetylation; Animals; Antibodies; Apoptosis; Biotechnology; Cardiomyocytes; Cardiomyopathy; Cell death; Deacetylation; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetic Cardiomyopathies - drug therapy; Diabetic Cardiomyopathies - etiology; Diabetic Cardiomyopathies - prevention & control; Enzymes; Ferroptosis; Fibronectin; Fibronectins; Gene expression; Glucose; Glutathione peroxidase; Health risks; Heart; Humans; Irisin; Ischemia; Laboratory animals; Life sciences; Lipid peroxidation; Lipids; Mice; Myocytes, Cardiac; p53; p53 Protein; Pathogenesis; Peptides; Proteins; Reperfusion; SIRT1; SIRT1 protein; Sirtuin 1; Streptozocin; Transmission electron microscopy; Tumor Suppressor Protein p53; Type 1 diabetic cardiomyopathy
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-024-02183-5

Diabetic cardiomyopathy (DCM) is a serious complication in patients with type 1 diabetes mellitus (T1DM), which still lacks adequate therapy. Irisin, a cleavage peptide off fibronectin type III domain-containing 5, has been shown to preserve cardiac function in cardiac ischemia-reperfusion injury. Whether or not irisin plays a cardioprotective role in DCM is not known. T1DM was induced by multiple low-dose intraperitoneal injections of streptozotocin (STZ). Our current study showed that irisin expression/level was lower in the heart and serum of mice with STZ-induced TIDM. Irisin supplementation by intraperitoneal injection improved the impaired cardiac function in mice with DCM, which was ascribed to the inhibition of ferroptosis, because the increased ferroptosis, associated with increased cardiac malondialdehyde (MDA), decreased reduced glutathione (GSH) and protein expressions of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), was ameliorated by irisin. In the presence of erastin, a ferroptosis inducer, the irisin-mediated protective effects were blocked. Mechanistically, irisin treatment increased Sirtuin 1 (SIRT1) and decreased p53 K382 acetylation, which decreased p53 protein expression by increasing its degradation, consequently upregulated SLC7A11 and GPX4 expressions. Thus, irisin-mediated reduction in p53 decreases ferroptosis and protects cardiomyocytes against injury due to high glucose. This study demonstrated that irisin could improve cardiac function by suppressing ferroptosis in T1DM via the SIRT1-p53-SLC7A11/GPX4 pathway. Irisin may be a therapeutic approach in the management of T1DM-induced cardiomyopathy.